Sutro BiopharmaEigentümerstruktur
| Preis (2026-07-30) | 52W Hoch | 52W Tief |
| 24.82 USD | 43,85 USD | 7,15 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 47,75 USD | 4 | 0 | 5 | 1 | 0 |
| #Shares | Short [%] | Short Ratio |
| 16.570.439 | 10,01 | 3,51 |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Sutro Biopharma
Mitarbeiter 133
Handelsplatz NASDAQ
Ticker Symbol STRO
IPO Datum 2018-09-27
Adresse 111 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Webseite https://www.sutrobio.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Ms. Jane Chung R.Ph. | CEO & Director |
| 2 | Mr. Gregory K. Chow BA, CPA, MBA | Chief Financial Officer |
| 3 | Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
| 4 | Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
| 5 | Mr. Devendra Luhar | Senior Vice President of Technical Operations |
| 6 | Mr. David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel |
| 7 | Ms. Kari E. Leetch | Senior VP and Head of People & Culture |
| 8 | Mr. Jonathan Fawcett DPHIL, MBBS | VP & Head of Clinical Development |
| 9 | Ms. Regina Cheng | Vice President & Controller |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
| Rang | Inhaber | Anteile | Wert |
|---|---|---|---|
| 1 | Bvf Inc | 0,00% | 0,00 Mio. USD |
| 2 | Affinity Asset Advisors, LLC | 0,00% | 0,00 Mio. USD |
| 3 | Samsara BioCapital, LLC | 0,00% | 0,00 Mio. USD |
| 4 | Kynam Capital Management, LP | 0,00% | 0,00 Mio. USD |
| 5 | Orbimed Advisors, LLC | 0,00% | 0,00 Mio. USD |
| 6 | Vanguard Capital Management, LLC | 0,00% | 0,00 Mio. USD |
| 7 | Eventide Asset Management, LLC | 0,00% | 0,00 Mio. USD |
| 8 | Perceptive Advisors LLC | 0,00% | 0,00 Mio. USD |
| 9 | RA Capital Management, LLC | 0,00% | 0,00 Mio. USD |
| 10 | Point72 Asset Management, L.P. | 0,00% | 0,00 Mio. USD |
| 11 | ADAR1 Capital Management LLC | 0,00% | 0,00 Mio. USD |
| 12 | Velan Capital Investment Management LP | 0,00% | 0,00 Mio. USD |
| 13 | Balyasny Asset Management LLC | 0,00% | 0,00 Mio. USD |
| 14 | Woodline Partners LP | 0,00% | 0,00 Mio. USD |
| 15 | UBS Group AG | 0,00% | 0,00 Mio. USD |
| 16 | Vanguard Group Inc | 0,00% | 0,00 Mio. USD |
| 17 | Acadian Asset Management LLC | 0,00% | 0,00 Mio. USD |
| 18 | Merck & Co Inc | 0,00% | 0,00 Mio. USD |
| 19 | Longwood Capital Partners LLC | 0,00% | 0,00 Mio. USD |
| 20 | BlackRock Inc | 0,00% | 0,00 Mio. USD |